Share on StockTwits

Nektar Therapeutics (NASDAQ:NKTR) will be issuing its Q114 quarterly earnings data on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $53.99 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.24. The company had revenue of $31.15 million for the quarter, compared to the consensus estimate of $49.26 million. The company’s quarterly revenue was up 47.3% on a year-over-year basis. On average, analysts expect Nektar Therapeutics to post $-0.72 EPS for the current fiscal year and $0.12 EPS for the next fiscal year.

Nektar Therapeutics (NASDAQ:NKTR) opened at 11.72 on Tuesday. Nektar Therapeutics has a one year low of $8.72 and a one year high of $15.34. The stock has a 50-day moving average of $11.95 and a 200-day moving average of $12.02. The company’s market cap is $1.484 billion.

A number of research firms have recently commented on NKTR. Analysts at Jefferies Group reiterated a “buy” rating on shares of Nektar Therapeutics in a research note on Tuesday, April 29th. They now have a $15.00 price target on the stock. Finally, analysts at MKM Partners downgraded shares of Nektar Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, February 27th. They now have a $13.00 price target on the stock. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $15.99.

Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.